The agency first approved Soliris in 2007 to treat paroxysmal nocturnal hemoglobinuria, a rare, life-threatening blood disease. The drug may now also be used to treat adults with generalized myasthenia gravis — an autoimmune disorder that affects the body’s intramuscular system.
Soliris is the first treatment approved to treat generalized myasthenia gravis in more than 60 years.
More articles on supply chain:
Woman finds pile of ‘hundreds’ of expired medical supplies outside Dallas hospital
FDA issues warning letter to Magellan over violations related to blood-lead tests
Hospitals grapple with medical supply shortages in wake of Hurricane Maria: 4 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
